Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

ACRS

NASDAQ

Aclaris Therapeutics (ACRS)

3.45 USD −1.43% vs prior close Nov 20, 2026
Aclaris Therapeutics, Inc. price graph
64 sessions
7 3 24 Aug 20 Nov

The line runs 6.30 USD on 24 August through 3.45 USD on 20 November, on a scale from 3 to 7. Days the market did not trade hold the previous close, flat.

Market cap
547.2M USD
Revenue, year to Dec 2025
7.8M USD
EPS, diluted, year to Dec 2025
−0.53 USD
52-week range
2.33 USD – 6.54 USD
Avg volume
212.8K

as of Nov 20, 2026

Have Aclaris Therapeutics (ACRS) insiders bought or sold shares recently?

ACRS's newest Form 4 filing is dated 1 August 2026: none in the last 90 days.

Form 4

Have Aclaris Therapeutics (ACRS) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
23 Apr 2026Leonard Braden Michael10% OwnerSell300,0001.4M USD
36 other filings: grants, exercises, tax withholding and transfers, not trades
Have Aclaris Therapeutics (ACRS) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
01 Aug 2026Kolbeck Roland WilhelmChief Scientific OfficerOption exercise36,375
01 Aug 2026Kolbeck Roland WilhelmChief Scientific OfficerTax withheld12,38564K USD
05 Jun 2026SCHIFF ANDREW NDirectorOption exercise11,580
05 Jun 2026MILANO VINCENTDirectorOption exercise11,580
05 Jun 2026GOWEN MAXINEDirectorOption exercise11,580
05 Jun 2026Mehra AnandDirectorOption exercise11,580
05 Jun 2026Molineaux Christopher P.DirectorOption exercise11,580
05 Jun 2026Humphries William D.DirectorOption exercise11,580
01 May 2026Hall Jesse WayneChief Medical OfficerOption exercise36,375
01 May 2026Hall Jesse WayneChief Medical OfficerTax withheld9,33041K USD
01 Mar 2026Balthaser KevinChief Financial OfficerOption exercise2,375
01 Mar 2026Balthaser KevinChief Financial OfficerTax withheld6772K USD

Showing the 12 most recent of 36 compensation filings in this window. The figures above count all of them.

Which funds hold Aclaris Therapeutics (ACRS)?

7 of the 45 institutional funds we track reported a Aclaris Therapeutics position for the quarter ended 30 Sep 2026 — a combined 21.6M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Aclaris Therapeutics (ACRS)?
FundPositionSharesValueShares q/q
Citadel AdvisorsHeld (±25%)1,775,4959.3M USD+0.8%
Balyasny Asset ManagementTrimmed1,410,2997.4M USD−30.3%
Marshall WaceNew position630,8573.3M USD
Two Sigma InvestmentsTrimmed98,668519K USD−25.9%
Renaissance TechnologiesTrimmed82,812436K USD−89.9%
AQR Capital ManagementHeld (±25%)63,124332K USD+4.8%
Millennium ManagementTrimmed50,673267K USD−90.3%
D. E. Shaw & Co.Exited

What has been filed or recorded for Aclaris Therapeutics (ACRS)?

The filings we hold for Aclaris Therapeutics, newest first: 6 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 26 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Aclaris Therapeutics (ACRS)?
And
26 Oct 2026Fails to deliverShares failed to deliver4,908 shares18K USD notional · 0.003% of shares out
22 Oct 2026Fails to deliverShares failed to deliver4,994 shares19K USD notional · 0.003% of shares out
21 Oct 2026Fails to deliverShares failed to deliver999 shares4K USD notional · 0.001% of shares out
14 Oct 2026Fails to deliverShares failed to deliver10 shares35 USD notional · <0.001% of shares out
09 Oct 2026Fails to deliverShares failed to deliver706 shares3K USD notional · <0.001% of shares out
08 Oct 2026Fails to deliverShares failed to deliver1,799,502 shares6.1M USD notional · 1.135% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.12 USD
30 Sep 2026FinancialsTotal assets216.2M USDat period end
30 Sep 2026FinancialsTotal equity166.8M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.15 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.15 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −0.53 USD
31 Dec 2025FinancialsRevenue7.8M USDfiscal year
31 Dec 2025FinancialsNet income−64.9M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−0.53 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.12 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.13 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.12 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −1.71 USD

What do people ask about Aclaris Therapeutics (ACRS)?

From live data
What did Aclaris Therapeutics shares close at?3.45

Aclaris Therapeutics closed at 3.45 USD on 20 Nov 2026, down 1.43% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Aclaris Therapeutics’ market cap?547.2M

Aclaris Therapeutics is worth 547.2M USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.

What is Aclaris Therapeutics’ revenue?7.8M

Aclaris Therapeutics reported revenue of 7.8M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Aclaris Therapeutics insiders bought or sold shares recently?

No Aclaris Therapeutics insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 1 Aug 2026 (SEC Form 4). See Insiders

Which funds own Aclaris Therapeutics?7 of 45

7 of the 45 funds we track reported a Aclaris Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Citadel Advisors, Balyasny Asset Management and Marshall Wace. See Funds

When did Aclaris Therapeutics last report earnings?−0.12

Aclaris Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.12 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings
  9. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words